Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,220,596
  • Shares Outstanding, K 203,532
  • Annual Sales, $ 0 K
  • Annual Income, $ -413,840 K
  • EBIT $ -487 M
  • EBITDA $ -487 M
  • 60-Month Beta 0.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.40

Options Overview Details

View History
  • Implied Volatility 77.02% (+12.27%)
  • Historical Volatility 46.25%
  • IV Percentile 69%
  • IV Rank 22.85%
  • IV High 173.11% on 10/22/25
  • IV Low 48.56% on 08/29/25
  • Expected Move (DTE 6) 1.96 (7.98%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 125
  • Volume Avg (30-Day) 615
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 38,121
  • Open Int (30-Day) 31,805
  • Expected Range 22.55 to 26.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.60
  • Number of Estimates 9
  • High Estimate $-0.52
  • Low Estimate $-0.71
  • Prior Year $-0.64
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.79 +7.50%
on 03/20/26
25.96 -5.62%
on 03/11/26
-1.22 (-4.74%)
since 03/10/26
3-Month
22.79 +7.50%
on 03/20/26
29.25 -16.24%
on 02/25/26
-1.53 (-5.88%)
since 01/09/26
52-Week
13.36 +83.38%
on 05/08/25
29.25 -16.24%
on 02/25/26
+9.71 (+65.65%)
since 04/10/25

Most Recent Stories

More News
Stocks Sink as President Trump Signals Iran War Will Drag On

The S&P 500 Index ($SPX ) (SPY ) today is down -1.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. June E-mini S&P futures...

ALK : 39.50 (-1.00%)
APO : 104.28 (-2.52%)
GOOGL : 317.24 (-0.39%)
ARES : 100.46 (-4.14%)
AAPL : 260.48 (unch)
SNDK : 851.77 (+0.02%)
HL : 19.46 (+0.83%)
CDE : 20.24 (+2.64%)
OXY : 57.97 (-0.96%)
TSLA : 348.95 (+0.96%)
FANG : 188.21 (+1.02%)
STX : 503.13 (+0.47%)
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated...

IMVT : 24.50 (-4.48%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders.  The investigation seeks...

IMVT : 24.50 (-4.48%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the...

IMVT : 24.50 (-4.48%)
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide...

IMVT : 24.50 (-4.48%)
ROIV : 28.21 (-0.95%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders.  The investigation seeks...

IMVT : 24.50 (-4.48%)
Immunovant Announces Pricing of $550 Million Common Stock Financing

Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company...

IMVT : 24.50 (-4.48%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing...

IMVT : 24.50 (-4.48%)
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business...

IMVT : 24.50 (-4.48%)
ROIV : 28.21 (-0.95%)
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s...

IMVT : 24.50 (-4.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 26.58
2nd Resistance Point 26.15
1st Resistance Point 25.33
Last Price 24.50
1st Support Level 24.08
2nd Support Level 23.65
3rd Support Level 22.83

See More

52-Week High 29.25
Last Price 24.50
Fibonacci 61.8% 23.18
Fibonacci 50% 21.31
Fibonacci 38.2% 19.43
52-Week Low 13.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.